Business
Race Oncology (ASX:RAC) share price slides on a new melanoma preclinical study
The Race Oncology Ltd (ASX: RAC) share price is sliding today, despite the announcement of a new preclinical study by the specialty pharmaceutical company. At the time of writing, shares are down 0.5% to $3.98.
Race Oncology share price unfazed by Bisantrene study
Race Oncology focuses on the development of cancer-targeting drugs in an effort towards better outcomes. The company’s flagship drug is Bisantrene, a small molecule inhibitor of the fat mass and obesity-associated (FTO) protein. A link between FTO and a range of cancers has led Race to investigate Bisantrene further.
According to the release, Race has now entered…
-
General15 hours agoBali scooter crash victim Keanu Neilsen’s surgery could cost more than $100,000
-
Noosa News19 hours agoOprah Winfrey Is Getting Chatting in Australia and NZ in 2025 on Her First Down Under Tour in a Decade
-
General22 hours agoAUKUS delusions. More rivets pop in submarine drama
-
Noosa News12 hours agoFormer Channel Nine reporter Benjamin McCormack facing dozens of child abuse material charges in Brisbane